Table: q1_q4_2021_prescription_drugs_intro_to_market , manufacturer_name like J*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

manufacturer_name	ndc_number	drug_product_description	date_introduced_to_market	wac_at_introduction	marketing_pricing_plan_description	marketing_pricing_plan_non_public_indicator	estimated_number_of_patients	breakthrough_therapy_indicator	priority_review_indicator	acquisition_date	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	general_comments	supporting_documents
Janssen Biotech, Inc.	57894050101	RYBREVANT™ (amivantamab-vmjw), Strength: 350mg/7mL, Form: 1 Single Vial	2021-05-24	2986.4300	While specific marketing and pricing plans are not available in the public domain, generally we plan to market in the US and promote to appropriate healthcare professionals who treat individuals diagnosed with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion. The pricing plan has WAC set for 350 mg / 7 mL vial at $2,986.43. The list price of RYBREVANT™ is not reflective of discounts and rebates which may be available through Medicaid, Medicare, and commercial insurance. RYBREVANT™ will also be discounted as required under the 340B program, Federal Supply Schedule, and other government programs. International approvals are pending.	None	None	1	1	None	None	None	None	The estimated number of patients in the United States with a condition for which RYBREVANT™ may be prescribed is not in the public domain or publicly available.	None
Janssen Pharmaceuticals, Inc.	50458070714	PONVORY™ (ponesimod) Starter Pack Strength:10MG Form:Tablet	2021-03-24	3772.3000	While specific marketing and pricing plans are not available in the public domain, generally we plan to market in the US and promote to appropriate healthcare professionals who treat individuals diagnosed with Relapsing forms of Multiple Sclerosis (RMS). The pricing plan has WAC set for the Multiple Strength, Titration Pack 14 set at $3,772.30. The list price of PONVORY is not reflective of discounts and rebates which may be available through Medicaid, Medicare, and commercial insurance. PONVORY will also be discounted as required under the 340B program, Federal Supply Schedule, and other government programs. International approvals are pending.	None	None	None	None	None	None	None	None	Janssen's estimated volume of patients who may be prescribed PONVORY is not available in the public domain. This was not an acquisition.	None
Janssen Pharmaceuticals, Inc.	50458072030	PONVORY™ (ponesimod) Strength:20MG Form:Tablet	2021-03-24	8083.5000	While specific marketing and pricing plans are not available in the public domain, generally we plan to market in the US and promote to appropriate healthcare professionals who treat individuals diagnosed with Relapsing forms of Multiple Sclerosis (RMS). The pricing plan has WAC set for a 30 day supply of the 20 mg maintenance dose at $8,083.50. The list price of PONVORY is not reflective of discounts and rebates which may be available through Medicaid, Medicare, and commercial insurance. PONVORY will also be discounted as required under the 340B program, Federal Supply Schedule, and other government programs. International approvals are pending.	None	None	None	None	None	None	None	None	Janssen's estimated volume of patients who may be prescribed PONVORY is not available in the public domain. This was not an acquisition.	None
Janssen Pharmaceuticals, Inc.	50458057501	XARELTO® for Oral Suspension Strength: 1 mg/mL, Form: Suspension, Reconstituted, Oral	2021-12-28	492.5000	While specific marketing and pricing plans are not available in the public domain, generally we plan to market XARELTO® for Oral Suspension in the US through non-personal channels to appropriate healthcare professionals who treat pediatric patients that fall within approved indications. The pricing plan has WAC set for 155mg at $492.50 for a 30-day maintenance dose. . The list price of XARELTO® for Oral Suspension is not reflective of discounts and rebates which may be available through Medicaid, Medicare, and commercial insurance. XARELTO® for Oral Suspension will also be discounted as required under the 340B program, Federal Supply Schedule, and other government programs.	None	1560	None	None	None	None	None	None	The 1,560 estimated number of patients reflects the CDC.gov estimate of the annual incidence of Venous Thromboembolism (VTE) in children of up to 2.1 per 100,000, applied to the US child population of 74.3 million (from childstats.gov.)	None
Jazz Pharmaceuticals, Inc.	68727090003	Rylaze, one carton containing 3 single dose vials, each single dose vial contains 10 mg/0.5 mL solution of asparaginase erwinia chrysanthemi (recombinant)-rywn	2021-07-15	13170.0000	None	1	6000	None	None	None	None	None	None	None	None